Pancreatic Cancer Research

ResearcherLeiden University Medical CenterActive in the last 2 years

Lydia G. van der Geest

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1637-5520; OpenAlex author ID A5083282780. Sources: OpenAlex.

Their work

Papers
55 (first author 6, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
118
Papers, trials and grants by year

2016: 4 papers · 2017: 3 papers · 2018: 7 papers · 2019: 4 papers · 2020: 6 papers · 2021: 5 papers · 2022: 4 papers · 2023: 4 papers · 2024: 2 papers · 2025: 8 papers · 2026: 8 papers

Papers 50 of 55

  1. Pancreatic cancer risk and survival in patients with Lynch syndrome: a nationwide Dutch cohort study. Co-author DOI 10.1016/j.eclinm.2026.103755↗
  2. Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes. Co-author DOI 10.1016/j.ejca.2026.116263↗
  3. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  4. Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A population-based study. Co-author DOI 10.1016/j.ejca.2026.116943↗
  5. The impact of lower household income and distance to hospital on treatment and survival in patients with localized pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.116956↗
  6. Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide population-based analysis. Last author DOI 10.1016/j.hpb.2025.12.035↗
  7. Gastrointestinal symptoms and health-related quality of life before and after pancreatectomy for pancreatic cancer (GO-PANC): longitudinal nationwide study. Co-author DOI 10.1093/bjs/znag122↗
  8. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  9. Survival scenarios of patients with localized and metastatic pancreatic adenocarcinoma: A population-based study. Co-author DOI 10.1002/ijc.35267↗
  10. Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis. Co-author DOI 10.1007/s10689-025-00512-5↗
  11. Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study. Co-author DOI 10.1016/j.eclinm.2024.103068↗
  12. Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based … Co-author DOI 10.1016/j.ejca.2025.115385↗
  13. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Co-author DOI 10.1016/j.ejca.2025.116099↗
  14. Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort. First author DOI 10.1016/j.pan.2025.03.011↗
  15. Reply to Comments on "Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort". First author DOI 10.1016/j.pan.2025.07.012↗
  16. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  17. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  18. Gender differences in tumor characteristics, treatment allocation and survival in stage I-III pancreatic cancer: a nationwide study. Last author DOI 10.1016/j.ejca.2024.114117↗
  19. Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.04.017↗
  20. Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis. Co-author DOI 10.1053/j.gastro.2023.02.032↗
  21. Impact of network treatment in patients with resected pancreatic cancer on use and timing of chemotherapy and survival. Co-author DOI 10.1093/bjsopen/zrad006↗
  22. Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival… Co-author DOI 10.1245/s10434-023-13465-9↗
  23. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33916↗
  24. Impact of multicentre diagnostic workup in patients with pancreatic cancer on repeated diagnostic investigations, time-to-diagnosis and time-to-treatment: A na… Co-author DOI 10.1016/j.ejso.2022.05.031↗
  25. Age and prognosis in patients with pancreatic cancer: a population-based study. First author DOI 10.1080/0284186x.2021.2016949↗
  26. Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study. Co-author DOI 10.3389/fonc.2022.839779↗
  27. Readily available biomarkers predict poor survival in metastatic pancreatic cancer. Co-author DOI 10.1080/1354750x.2021.1893814↗
  28. Incidence, Treatment, and Survival of Synchronous Peritoneal Metastases in Pancreatic Cancer: Update of a Nationwide Cohort. Co-author DOI 10.1097/mpa.0000000000001857↗
  29. Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large Internat… Co-author DOI 10.1097/sla.0000000000003558↗
  30. SOURCE-PANC: A Prediction Model for Patients With Metastatic Pancreatic Ductal Adenocarcinoma Based on Nationwide Population-Based Data. Co-author DOI 10.6004/jnccn.2020.7669↗
  31. First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort. Co-author DOI 10.6004/jnccn.2021.7028↗
  32. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.ejca.2019.11.002↗
  33. Nationwide compliance with a multidisciplinary guideline on pancreatic cancer during 6-year follow-up. Co-author DOI 10.1016/j.pan.2020.10.032↗
  34. Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. Co-author DOI 10.1080/0284186x.2020.1725241↗
  35. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled t… Co-author DOI 10.1186/s13063-020-4180-z↗
  36. Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. Co-author DOI 10.1245/s10434-020-08235-w↗
  37. Treatment and Survival of Elderly Patients with Stage I-II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium. Co-author DOI 10.1245/s10434-020-08539-x↗
  38. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis. Co-author DOI 10.1016/j.ejca.2018.10.008↗
  39. An international comparison of treatment and short-term overall survival for older patients with pancreatic cancer. Co-author DOI 10.1016/j.jgo.2019.02.006↗
  40. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Co-author DOI 10.1136/gutjnl-2017-314828↗
  41. Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a … Co-author DOI 10.1186/s12916-019-1304-y↗
  42. Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study. Co-author DOI 10.1002/cam4.1750↗
  43. Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: a large international population-based study. Co-author DOI 10.1002/ijc.31628↗
  44. Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands. First author DOI 10.1080/0284186x.2018.1470330↗
  45. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. Co-author DOI 10.1080/0284186x.2018.1518593↗
  46. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international populati… Co-author DOI 10.1186/s12916-018-1120-9↗
  47. Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium. Co-author DOI 10.1245/s10434-018-6705-1↗
  48. Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among… Co-author DOI 10.2147/clep.s160973↗
  49. Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. Co-author DOI 10.1002/bjs.10602↗
  50. Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. Co-author DOI 10.1002/cam4.1240↗

Closest collaborators

The 25 strongest of 118 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 40 shared papers, 2016–2026 · strength 5.51
  2. Johanna W. Wilmink · 29 shared papers, 2017–2026 · strength 4.83
  3. Judith de Vos‐Geelen · 26 shared papers, 2018–2026 · strength 4.40
  4. Hanneke W.M. van Laarhoven · 23 shared papers, 2016–2026 · strength 3.26
  5. Ignace H. J. T. de Hingh · 20 shared papers, 2016–2026 · strength 2.88
  6. Marjolein Y.V. Homs · 15 shared papers, 2020–2026 · strength 2.50
  7. Bas Groot Koerkamp · 16 shared papers, 2018–2026 · strength 2.24
  8. Casper H.J. van Eijck · 17 shared papers, 2016–2026 · strength 2.19
  9. Hjalmar C. van Santvoort · 13 shared papers, 2018–2026 · strength 2.06
  10. Jeanin Elise van Hooft · 11 shared papers, 2020–2026 · strength 2.05
  11. Bert A. Bonsing · 15 shared papers, 2018–2026 · strength 2.05
  12. Vincent Erwin de Meijer · 11 shared papers, 2020–2026 · strength 1.97
  13. Martijn W.J. Stommel · 11 shared papers, 2020–2026 · strength 1.96
  14. Izaak Quintus Molenaar · 11 shared papers, 2016–2026 · strength 1.67
  15. Lois A. Daamen · 7 shared papers, 2025–2026 · strength 1.44
  16. V.E.P.P. Lemmens · 17 shared papers, 2016–2021 · strength 1.39
  17. Pauline A. J. Vissers · 8 shared papers, 2018–2026 · strength 1.21
  18. Lodewijk A.A. Brosens · 6 shared papers, 2022–2026 · strength 1.05
  19. Merlijn U.J.E. Graus · 5 shared papers, 2023–2026 · strength 1.04
  20. Thijmen H.T. Broekman · 4 shared papers, 2026 · strength 0.94
  21. Esther N. Pijnappel · 4 shared papers, 2021–2025 · strength 0.70
  22. Anne M. Gehrels · 3 shared papers, 2024–2025 · strength 0.66
  23. Annette A. van Zweeden · 2 shared papers, 2025 · strength 0.66
  24. Marco J. Bruno · 4 shared papers, 2020–2026 · strength 0.61
  25. Tara M. Mackay · 5 shared papers, 2018–2026 · strength 0.60

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.